Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, John M. Bennett, Uma Borate, Andrew M. Brunner, Wanxing Chai-Ho, Peter Curtin, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Shira Dinner, Charles Foucar, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Brian A. Jonas, Sioban Keel, Yazan MadanatLori J. Maness, James Mangan, Shannon McCurdy, Christine McMahon, Bhumika Patel, Vishnu V. Reddy, David A. Sallman, Rory Shallis, Paul J. Shami, Swapna Thota, Asya Nina Varshavsky-Yanovsky, Peter Westervelt, Elizabeth Hollinger, Dorothy A. Shead, Cindy Hochstetler

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.

Original languageEnglish (US)
Pages (from-to)106-117
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume20
Issue number2
DOIs
StatePublished - Feb 2022

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this